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Crohn’s disease (CD) is an immune-mediated chronic intestinal condition that affects nearly 780,000 
patients in the United States. Patients with Crohn’s disease often present with various gastrointestinal 
(GI) symptoms in addition to other, more specific symptoms such as malabsorption and pertinent 
laboratory derangements (Peppercorn, 2019). For many of these patients, CD not only causes physical 
barriers to normal life but also presents social and mental barriers. The etiology of this disease is largely 
unknown currently; infectious, immunologic, and genetic factors are thought to play a role (Boyapati, 
2015). Treatment of Crohn’s disease is guideline-driven and focuses on obtaining remission of symptoms 
and maintaining remission. Many medications can achieve these goals and with the advent of antibody 
directed therapies, the number of medications with promise in this disease is rapidly growing. Many of 
the new medications pose a great opportunity for pharmacists to get involved in patient-centered 
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At the completion of this presentation, participants should be able to…
1. Identify Crohn’s disease (CD) and differentiate the disease from other 
inflammatory bowel diseases
2. Understand what is standard in the diagnosis of Crohn’s disease
3. Understand the goals of therapy and prognosis of Crohn’s disease
4. Accurately assess medication therapy in the treatment of Crohn’s disease
5. Understand the role of the pharmacist in Crohn’s disease
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Learning Objectives
What is Crohn’s Disease (CD)?
§ An immune-mediated chronic intestinal condition
§ One of two major types of Inflammatory Bowel Disease (IBD)
§ Crohn’s disease and ulcerative colitis (UC)
§ Characterized by diarrhea and abdominal pain
§ Crohn’s disease can involve any part of the GI tract and cause discontinuous 
lesions, known as “skip” lesions
§ Transmural process
§ UC differs in that it is often confined to the rectum and colon and causes continuous 
lesions
3
Freidman SA , Harrison’s Principles of Internal Medicine 20th ed. 2018
Hemstreet BA, Pharmacotherapy: A Pathophysiologic Approach 10th ed. 2018
Comparison of Inflammatory Bowel Diseases
Crohn’s Disease Ulcerative Colitis (UC)
Signs/Symptoms
§ Malaise and Fever
§ Abdominal Pain






§ Frequent bowel movements
§ Hematochezia frequently
§ Weight loss
§ Fever/Tachycardia (Severe UC)




§ Abdominal mass and tenderness
§ Perianal fissure or fistula
§ Hemorrhoids, fissures or perirectal abscesses
§ Iritis, uveitis, episcleritis, or conjunctivitis




§ Increased white blood cell count, eosinophil sedimentation 
rate (ESR) or C-Reactive Protein (CRP)
§ (+) anti-Saccharomyces cerevisiae antibodies
§ Decreased hematocrit/hemoglobin
§ Increased eosinophil sedimentation rate (ESR) or C-
Reactive Protein (CRP)
§ Leukocytosis/Hypoalbuminemia (Severe UC)
§ (+) perinuclear antineutrophil cytoplasmic antibodies
Adapted from Hemstreet BA, Pharmacotherapy: A Pathophysiologic Approach 10th ed. 2018
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Etiology
§ Exact etiology is unknown 
§ Very complex
§ Immune mediated condition in genetically susceptible individuals whose onset is triggered by 
environmental factors that:
§ Perturb the mucosal barrier of the intestines
§ Alter healthy balance of gut microbiota
§ Abnormally stimulate gut immune responses
§ Infectious processes may also play a part in Crohn’s disease as well
§ One theory involves abnormal NOD-2 function which leads to a possible sustained 
inflammatory and immune response against gut microbiota
13Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn’s Disease. F1000Prime Report
NOD-2’s Effect on Intestinal Function
§ NOD-2
§ Pattern recognition receptor that controls immunity 
against intracellular bacteria
§ Activates nuclear factor-kappa-B (NF-κB)
§ NF-κB activation results in:
§ Production of mucin
§ Provides barrier protection against bacteria
§ Anti-microbial peptide that kills any bacteria that 
gets too close to the mucous membrane
§ Also plays a role in the release of pro-inflammatory 
cytokines such as IL-1β, IL-6, and IL-23
§ Any loss of function mutation in NOD-2 disrupts 
intestinal homeostasis
14Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn’s Disease. F1000Prime Report
From: Philpott DJ. NOD Proteins: Regulators of Inflammation in Health and Disease. 
Nature Reviews Immunology, 2014; Volume 14 Issue 1
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From: Philpott DJ. NOD Proteins: Regulators of Inflammation in Health and Disease. 
Nature Reviews Immunology, 2014; Volume 14 Issue 1
Infectious Factors
§ Shift toward proinflammatory 
bacteria (also known as dysbiosis)
§ Increased numbers of mucus, 
mucosal, and intraepithelial bacteria
§ Saccharomyces cerevisiae
antibodies
§ Demonstrates immunologic 
response to intestinal 
microorganisms
§ Bacterial gene products may:
§ Promote alteration of intestinal 
barrier
§ Propagate inflammatory response
16









Hemstreet BA, Pharmacotherapy: A Pathophysiologic Approach 10th ed. 2018
Clinical Presentation and Differential Diagnosis
Clinical Presentation of Crohn’s Disease
Abdominal Pain
Diarrhea
Hematochezia (less frequent than in UC)
Fistulas
Malabsorption














Peppercorn MA. Clinical manifestations, diagnosis, and prognosis of Crohn’s Disease;  UpToDate, 2019
Laboratory Values and Diagnosis
§ Diagnosis made based on a combination of:
§ Clinical presentation
§ Endoscopic findings
§ Ileocolonoscopy with biopsy should 





§ Lab testing is complementary and helps 
determine:
§ Disease severity
§ Complications of Crohn’s disease
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Laboratory Tests for Assessing Crohn’s Disease
Complete Blood Count
Blood Chemistry (Electrolytes, Renal Function, Liver 
Function Tests)
Eosinophil Sedimentation Rate ↑
C-Reactive Protein ↑
Serum Iron ↓
Serum Vitamin B12 ↓
Fecal Calprotectin ↑
Fecal Lactoferrin ↑
Stool Testing (to rule out C. difficile)
Peppercorn MA. Clinical manifestations, diagnosis, and prognosis of Crohn’s Disease;  UpToDate, 2019
Lichenstein, GR. ACG Clinical Guideline: Management of Crohn’s Disease in Adults.  Am J Gastroenterol. 2018;113(4)
Sequalae of Crohn’s Disease 
§ Risk Factors
§ Long-duration of disease
§ Extensive disease
§ Bypassed colon segments
§ Colon strictures
§ Primary sclerosing cholangitis
§ Family history of colon cancer











Freidman SA , Harrison’s Principles of Internal Medicine 20th ed. 2018
Determining and Monitoring Disease Activity
Methods in Determining Disease Activity
§ Fecal calprotectin
§ Levels > 100 mcg/g indicate recurrence
§ Fecal lactoferrin
§ CRP
§ Levels >15 mg/L at baseline may 
predicate primary nonresponse to 
therapy 
§ Crohn’s Disease Activity Index (CDAI)
§ Harvey Bradshaw Index
20Lichenstein, GR. ACG Clinical Guideline: Management of Crohn’s Disease in Adults.  Am J Gastroenterol. 2018;113(4)
Categories of Disease Activity
§ Remission
§ Mild (ambulatory, eating/drinking normally, 
<10% weight loss, no complications)
§ Moderate
§ Severe (cachectic with significant weight loss, 
complications, symptoms despite therapy)
§ Fulminant
Determining and Monitoring Disease Activity
§ CDAI and Harvey Bradshaw index 
are very similar and evaluate the 
same measures
§ Scores from these indices 
correlate with severity of current 
disease
21
Item (Daily Sum per Week) Weighting Factor
Number of liquid or very soft stools 2
Abdominal pain score in 1 week (rating 0-3) 5
General well-being (rating 1-4) 7




§ Anal disease (fissure/fistula, etc.)
§ Fever over 37.8°C
20
Antidiarrheal Use 30
Abdominal Mass (no = 0; equivocal = 2; yes = 5) 10
Males <47 hematocrit; Females <42 hematocrit 6
1-x(body weight divided by standard weight) 1
Crohn’s Disease Activity Index
Freeman HJ. Use of the Crohn’s Disease Activity Index in Clinical Trials of Biological Agents. World J Gastroenerol. 2008:14(26)













Hemstreet BA, Pharmacotherapy: A Pathophysiologic Approach 10th ed. 2018
Approach to Therapy
23




Severity of disease 
will determine 





Hemstreet BA, Pharmacotherapy: A Pathophysiologic Approach 10th ed. 2018
Non-Pharmacologic Therapy
Nutritional Support
§ Exclusion diets generally not supported
§ Avoidance of dairy may improve diarrheal symptoms if 
patient has lactase deficiency
§ Patients with small bowel strictures should avoid nuts to 
prevent obstruction 
Probiotic Administration
§ Has been explored and is thought to:
§ Re-establish normal bacterial flora
§ Reduce bacterial adhesion
§ Compete for nutrients with pathogenic bacteria
§ Produce antibacterial substances
§ Not recommended due to lack of evidence
24Hemstreet BA, Pharmacotherapy: A Pathophysiologic Approach 10th ed. 2018
Surgery
§ Many patients will require surgery even with 
expanding pharmacologic options
§ Often involves resection of segments of 
intestine that are affected, drainage of 
abscesses, or correction of fistulas
§ Usually reserved for patients with 
complications (fissures, strictures, etc.) 
despite medical management
§ High rate of recurrence even with resection
25








Corticosteroids Budesonide (Entocort EC
®, Uceris®)
Prednisone (Deltasone®, predniSONE®)
5-Aminosalicylates Mesalamine (Asacol HD






Lichenstein, GR. ACG Clinical Guideline: Management of Crohn’s Disease in Adults.  Am J Gastroenterol. 2018;113(4)
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Commonly Used Medications in Crohn’s Disease
Drug Mechanism of Action Dose Route of Administration
Budesonide (Entocort EC®) Corticosteroid Induction: 9 mg once daily for up to 8 weeks Oral
Sulfasalazine (Azulfidine®) 5-Aminosalacylic Acid 3 to 6 g daily Oral
Azathioprine (Azasan®, Imuran®) Purine Synthesis Inhibitor 50 mg PO daily (1.5-2.5 mg/kg/day) Intravenous
6-Mercaptopurine (Purixan®) Purine Antagonist 50 mg PO daily (0.75-1.5 mg/kg/day) Oral
Methotrexate (Otrexup®, Rasuvo®) Dihydrofolate Reductase Inhibitor




Lexi-Drugs Online™.  Lexi-Comp Online™.  Hudson (OH): Lexi-Comp, Inc.; 2019
Veauthier B. Crohn’s Disease and Management. Am Fam Physician. 2018
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Adverse Effects and Monitoring of Commonly Used Medications in Crohn’s Disease
Drug Adverse Reactions Monitoring
Budesonide (Entocort EC®)
Diarrhea, nausea, arthralgias, 
headache, respiratory tract infection, 
sinusitis
§ Signs and symptoms (S/S) 
of hyperadrenocorticism
§ S/S of adrenal suppression 
with long term therapy
Sulfasalazine (Azulfidine®)
Skin rash, dyspepsia, anorexia, 
oligospermia, leukopenia, abnormal 
hepatic function
§ Complete blood count 
(CBC) with differential
§ Liver function tests 
(LFTs)
§ Serum creatinine
Lexi-Drugs Online™.  Lexi-Comp Online™.  Hudson (OH): Lexi-Comp, Inc.; 2019
Veauthier B. Crohn’s Disease and Management. Am Fam Physician. 2018
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Adverse Effects and Monitoring of Commonly Used Medications in Crohn’s Disease
Drug Adverse Reactions Monitoring
Azathioprine (Azasan®, Imuran®)
Gastritis, nausea, vomiting, lymphoma, 
fever
May cause pancreatitis, leukopenia, 
anemia, thrombocytopenia
§ CBC with differential and 
platelets
§ Weekly x 1 month
§ Every other week x 2 
months
§ Monthly thereafter





encephalopathy, pancreatitis, rash, 
hyperpigmentation, lymphoma, fever
§ CBC with differential weekly 
during induction
§ LFTs weekly during induction
§ Serum Creatinine
Methotrexate (Otrexup®, Rasuvo®)
Alopecia, photosensitivity, rash, diarrhea, 
anorexia, nausea, vomiting, stomatitis, 
leukopenia, pneumonitis
May also cause hyperuricemia, 
gastrointestinal hemorrhage, 
myelosuppression, hepatotoxicity, lung 
fibrosis, renal failure
§ CXR at baseline
§ CBC with differential and 
platelets at baseline then 
monthly
§ Blood Urea Nitrogen (BUN), 
serum creatinine, and LFTs 
baseline then every 4-8 weeks
Lexi-Drugs Online™.  Lexi-Comp Online™.  Hudson (OH): Lexi-Comp, Inc.; 2019
Veauthier B. Crohn’s Disease and Management. Am Fam Physician. 2018
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Biologics Used in the Treatment of Crohn’s Disease
Drug Dose Route of Administration Mechanism of Action
Adalimumab 
(Humira®)
Induction: 160 mg then 80 mg two weeks later
Subcutaneous
Anti-TNFα
Maintenance: 40 mg every other week
Certolizumab 
(Cimzia®)
Induction: 400 mg at weeks 0, 2, and 4
Subcutaneous
Maintenance: 400 mg every four weeks
Infliximab 
(Remicade®)
Induction: 5 mg/kg at weeks 0, 2, and 6
Intravenous
Maintenance: 5-10 mg/kg every 8 weeks
Natalizumab 
(Tysabri®)




Maintenance: 300 mg every four weeks
Vedolizumab 
(Entyvio®)
Induction: 300 mg at weeks 0, 2, and 6
Intravenous








56 to 85 kg: 390 mg
>85 kg: 520 mg
Maintenance: 90 mg every eight weeks 
starting eight weeks after induction Subcutaneous
Adapted From: Biologics for Crohn’s Disease. Pharmacist’s Letter/Prescriber’s Letter. 2018;25(7)
Adverse Effects and Monitoring of Biologics Used in the Treatment of Crohn’s Disease
Drug Adverse Reactions Monitoring
Adalimumab 
(Humira®)
Injection site reactions, infection, tuberculosis (TB), 
malignancies, autoantibodies/lupus-like syndrome
§ Purified protein derivative 
test at baseline
§ Chest x-ray (CXR) at 
baseline
§ S/S of tuberculosis and 
active hepatitis B (in 
hepatitis B carriers)
§ CBC




Injection site reactions, upper respiratory tract 




Acute or delayed infusion reactions (arthralgia, 
myalgia, fever, malaise, hives, angioedema, 
lymphadenopathy, itching), infections, pneumonia, 
cellulitis, abscess, skin ulceration, sepsis, bacterial 
infection, lymphoma, autoantibodies/lupus-like 
syndrome
Adapted From: Veauthier B. Crohn’s Disease and Management. Am Fam Physician. 2018 30
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Adverse Effects and Monitoring of Biologics Used in the Treatment of Crohn’s Disease
Drug Adverse Reactions Monitoring
Natalizumab 
(Tysabri®)
Headache, fatigue, respiratory tract and other infections, 
nausea, arthralgia, depression, progressive multifocal 
leukencephalopathy (in patients that have Anti-John 
Cunnigham virus (JCV) antibodies), 
§ LFTs
§ Hypersensitivity reactions
§ S/S acute retinal necrosis
§ Anti-JCV antibody 
positivity
§ S/S of PML
Vedolizumab 
(Entyvio®)
Nasopharyngitis, headache, arthralgias, nausea, pyrexia, 
upper respiratory tract and other infections, 
hypersensitivity reactions, anaphylaxis, lupus-like syndrome
§ LFTs
§ TB screening




Vomiting, nasopharyngitis, injection site erythema, 
infections, pruritus
§ Purified protein derivative 
test at baseline
§ CXR at baseline
§ CBC




Adapted From: Veauthier B. Crohn’s Disease and Management. Am Fam Physician. 2018
Ustekinumab as Induction and Maintenance Therapy for Crohn’s 
Disease
§ Randomized, controlled double-blind trials
§ Two 8-week induction trials 
§ One 44-week maintenance trial 
32Feegan BG. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375
General Inclusion Criteria
§ At least 18 years old
§ Crohn’s Disease for at least 3 months
§ Score of 220 to 450 points on the CDAI
§ Objective evidence of active Crohn’s Disease
§ CRP >3.0 mg/dL
§ Fecal calprotectin >250 mg/kg
§ Endoscopic ulcerations
Ustekinumab as Induction and Maintenance Therapy for Crohn’s 
Disease
33Feegan BG. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375
Induction Trial Inclusion Criteria
§ Therapy with one or more Anti-TNFα agent
§ Primary non-response or secondary 
non-response
§ Treatment failure or unacceptable side 
effects with immunomodulators or 
corticosteroids
Maintenance Trial Inclusion Criteria
§ Completion of induction trial
Exclusion Criteria
§ History of treatment with IL-12 or IL-23 
antagonists
§ Treatment with IV glucocorticoids, Anti-TNFα
agents or natalizumab during wash-out period
§ Patients with GI conditions that might require 
surgery or preclude use of CDAI
§ Active infections
§ History of cancer
Ustekinumab as Induction and Maintenance Therapy for Crohn’s 
Disease








Responders at week 
8 randomized to…
SQ ustekinumab 
90 mg q 8 weeks
Placebo
SQ ustekinumab 
90 mg q 12 weeks
Ustekinumab as Induction Therapy for Crohn’s Disease
35Feegan BG. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375
Primary Endpoint for Induction Trials
§ Clinical response at week 6
§ Decrease from baseline CDAI of at least 100 points or a total CDAI <150
Secondary Endpoints for Induction Trials
§ Clinical remission at week 8  (CDAI <150)
§ Clinical response at week 8
§ Decrease in baseline CDAI of at least 70 points at week 8
§ Change in CDAI score
§ Change in CRP level/normalization of CRP level (<3.0 mg/L) at weeks 3, 6, and 8
§ Change in fecal calprotectin level/normalization of level (<250 mg or <100 mg/kg) at week 6
Ustekinumab as Induction Therapy for Crohn’s Disease Results
36Feegan BG. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375
Primary Endpoint— Clinical Response at week 6
IV ustekinumab 130 mg: 34.3% (P≤0.003)
IV ustekinumab 6 mg/kg: 33.7% (P≤0.003)
Placebo: 21.5% (P<0.001)
Secondary Endpoints (Clinical remission 6 and 8 weeks)
Favored ustekinumab 6 mg/kg over ustekinumab 130 mg and 
placebo for all secondary endpoints
Ustekinumab as Maintenance Therapy for Crohn’s Disease
37Feegan BG. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016;375
Primary Endpoint for Maintenance 
Trial
§ Clinical remission at week 44
§ Total CDAI <150
Secondary Endpoints for 
Maintenance Trial
§ Clinical response at week 44
§ Maintenance of remission among 
patients in remission at week 0 of 
IM-UNITI
Primary Endpoint— Clinical Remission at week 44
SQ ustekinumab every 8 weeks: 53.1% (P=0.005)
SQ ustekinumab every 12 weeks: 48.8% (P=0.04)
Placebo: 35.9% (P=0.005, P=0.04)
Secondary Endpoint— Clinical Response at week 44
SQ ustekinumab every 8 weeks: 44.3% (P=0.02)
SQ ustekinumab every 12 weeks: 58.1% (P=0.03)
Placebo: 59.4% (P=0.02, P=0.03)
Secondary Endpoint— Maintenance of Remission
Higher in 8-week (66.7%, P=0.007) and 12-week (56.4%, 
P=0.19) groups compared to placebo (45.6%)
Autoantibody Development
§ With all biologics used to treat Crohn’s disease, there is a risk for production of anti-drug antibodies (ADA)
§ More likely with chimeric monoclonal antibodies such as infliximab than humanized monoclonal antibodies 
such as adalimumab
§ In biologic-naïve patients, serum ADA is:
§ Detectable within 2-6 months of initiation of therapy
§ Undetectable after 12 months of therapy
§ Clinical effects of ADA development include:
§ Increased risk for hypersensitivity reactions
§ Diminished efficacy (which is generally seen with increasing doses to achieve similar clinical control)
§ Reduced cost-effectiveness
§ Co-treatment with an immunomodulator such as methotrexate or azathioprine is associated with decreased 
levels of serum ADA
38Strand V. Immunogenicity of Biologics in Chronic Diseases: A Systematic Review. BioDrugs. 2017
Therapeutic Drug Monitoring of Biologics in CD
§ Various drug threshold 
concentrations based on:
§ Disease phenotype
§ Desired therapeutic outcome
§ Importance of therapeutic drug 
concentrations
§ If a patient has adequate trough 
concentrations, ADA are unlikely 
to be relevant clinically
§ May be more cost effective than 
empiric dose escalation
39
Goal Drug Concentrations for Anti-TNF⍺ Agents
Infliximab Trough at week 14 >3 mcg/mL; >7 mcg/mL (increased mucosal healing)
Adalimumab
Trough at week 4 >5 mcg/mL; >7 mcg/mL 
(increased mucosal healing)
Maintenance trough >5 mcg/mL
Certolizumab pegol
Trough at week 6 >32 mcg/mL
Maintenance trough >15 mcg/mL
Goal Drug Concentrations for other Biologics
Vedolizumab Lacking evidence for specific goals; can be used to confirm detectable drug
Ustekinumab Lacking evidence for specific goals; can be used to confirm detectable drug
Papamichael K. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients with Inflammatory 
Bowel Diseases. Clin Gastroenterol Hepatol. 2019
Therapeutic Drug Monitoring of Biologics in CD
§ Anti-TNF⍺ Therapy
§ Recommendation to order 
drug/antibody concentration testing:
1. In responders and primary non-
responders at the end of 
induction
2. At least once during 
maintenance for all patients
3. For all anti-TNF ⍺ agents in 
patients with a confirmed 
secondary loss of response
40
§ Ustekinumab and Vedolizumab
§ Recommendation to order drug/antibody 
concentration testing:
1. In non-responders at the end of 
induction 
2. In patients with confirmed secondary 
loss of response
Papamichael K. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients with Inflammatory Bowel 
Diseases. Clin Gastroenterol Hepatol. 2019
American College of Gastroenterology’s 
Approach in Mild-Moderate Disease
Induction Therapy
§ Budesonide (Entocort EC®) 9 mg once 
daily in the morning for up to 8 weeks
§ Budesonide should be tapered by 3 mg 
increments every 2 to 4 weeks 
§ Preferred over prednisone due to a lower 
rate of systemic side effects
Maintenance Therapy
§ Sulfasalazine (Azulfidine®) 3 to 6 g/day 
for treatment of symptoms for up to 16 
weeks
§ Has not been shown to be more 
effective than placebo in achieving 
mucosal healing
§ No maintenance treatment in patients 
with mild disease is recommended 
provided they are asymptomatic
41Lichenstein, GR. ACG Clinical Guideline: Management of Crohn’s Disease in Adults.  Am J Gastroenterol. 2018;113(4)
American College of Gastroenterology’s 
Approach in Moderate-Severe Disease
Induction Therapy
§ Oral corticosteroids can be used short term to alleviate symptoms of moderate to severely 
active Crohn’s Disease
§ Prednisone equivalent doses of 40 to 60 mg/day maintained for 1-2 weeks
§ Taper 5 mg weekly until 20 mg/day then 2.5-5 mg weekly 
§ 1 in 5 patients will be steroid refractory
§ 1 in 3 patients will become steroid dependent and unable to taper due to symptoms
§ Vedolizumab (Entyvio®) and Natalizumab (Tysabri®) can also be used for induction of 
remission
42Lichenstein, GR. ACG Clinical Guideline: Management of Crohn’s Disease in Adults.  Am J Gastroenterol. 2018;113(4)
American College of Gastroenterology’s Approach in 
Moderate-Severe Disease Maintenance
§ Immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate may be used when 
a patient is steroid-refractory
§ Anti-TNFα agents can be used in patients are steroid-refractory and immunomodulator-refractory 
with or without immunomodulator therapy
§ Infliximab (Remicade®), Adalimumab (Humira®), or Certolizumab pegol (Cimzia®)
§ Ustekinumab (Stelara®) can be given to patients who have failed corticosteroids, 
immunomodulators or anti-TNFα agents or those who have had no prior anti-TNFα exposure
43Lichenstein, GR. ACG Clinical Guideline: Management of Crohn’s Disease in Adults.  Am J Gastroenterol. 2018;113(4)
American College of Gastroenterology’s 
Approach in Severe-Fulminant Disease
§ Intravenous corticosteroids
§ Parenteral methylprednisolone 40-60 mg/day
§ Anti-TNFα agents (infliximab, adalimumab, certolizumab pegol)
§ Infliximab for fulminant Crohn’s Disease
§ Adalimumab and certolizumab have not shown as clear of efficacy in fulminant disease
§ Thought to be because of infliximab’s weight-based dosing as patients can receive more 
medication
44
Induction and Maintenance Therapy









American Gastroenterological Association’s 
Crohn’s Disease Recommendations
Induction Therapy in Moderate-Severe 
Disease
§ In patients whose symptomology persists 




§ Anti-TNFα therapy + immunomodulator 
therapy






Terdiman JP. American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic 
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Terdiman JP. American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic 
Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn’s Disease. Gastroenterology. 2013;145(6)
The Study of Biologic and Immunomodulator Naïve Patients in Crohn’s 
Disease (SONIC) Trial
§ Randomized, double-blind, 30-week trial
§ 20-week extension in which blinding 
was maintained
§ Conducted at 92 centers from March 
2005 to March 2008
§ 508 patients
47Colombel JF. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. N Engl J Med. 2010:362(15)
Inclusion Criteria
§ At least 21 years old
§ Crohn’s Disease for at least 6 weeks
§ Score of 220 to 450 points on the CDAI
§ Corticosteroid dependent
§ Being considered for a second course of systemic 
steroids within 12 months
§ No response to at least 4 weeks of mesalamine or 
budesonide
The Study of Biologic and Immunomodulator Naïve Patients in Crohn’s 
Disease (SONIC) Trial
48Colombel JF. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. N Engl J Med. 2010:362(15)
Exclusion Criteria
§ No previous treatment with azathioprine, 6-mercaptopurine, methotrexate or an Anti-TNFα agent
§ History of short bowel syndrome, ostomy, symptomatic stricture, abscess
§ Abdominal surgery within previous 6 months
§ History of tuberculosis or other granulomatous infection
§ History of opportunistic infection within previous 6 months
§ Active infection with Hepatitis B or C
§ Infection with Human Immunodeficiency Virus
§ Multiple Sclerosis
§ Cancer
§ Homozygous mutant or heterozygous methyltransferase phenotype
The Study of Biologic and Immunomodulator Naïve Patients in Crohn’s 
Disease (SONIC) Trial
§ Randomized based on stratification 
according to duration of Crohn’s 
Disease and status with respect to 
corticosteroid dose
§ Infusions at 0, 2, 6, and then every 8 
weeks
49Colombel JF. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. N Engl J Med. 2010:362(15)
Groups Randomized to Receive
1. IV infliximab 5mg/kg + daily oral placebo capsules
2. Oral azathioprine 2.5 mg/kg daily + placebo infusions
3. IV infliximab 5mg/kg + oral azathioprine 2.5 mg/kg 
daily
The Study of Biologic and Immunomodulator Naïve Patients in Crohn’s 
Disease (SONIC) Trial
§ Primary Efficacy Endpoint:
§ Rate of corticosteroid-free 
remission at week 26
§ Secondary Efficacy Endpoints:
§ Rates of corticosteroid-free 
remission at other time points
§ Proportion of patients with mucosal 
healing at week 26 among those 
with mucosal ulcerations at 
baseline
§ Change in CRP level from baseline 
to week 26
50Colombel JF. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. N Engl J Med. 2010:362(15)
Clinical Remission




Clinical remission in 
patients who have not 
received systemic CS at 3 
weeks
The Study of Biologic and Immunomodulator Naïve Patients in Crohn’s 
Disease (SONIC) Trial Results
51Colombel JF. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. N Engl J Med. 2010:362(15)
Primary Endpoint— Corticosteroid-Free Remission
IV infliximab + oral azathioprine daily: 56.8% (P=0.02)
IV infliximab + daily oral placebo capsules: 44.4% (P=0.02)
Oral azathioprine daily + placebo infusions: 30.0% (P <0.001; P=0.006)
Secondary Endpoint— Corticosteroid-Free Remission, Mucosal Healing and Change 
in CRP Level :
Favored combination therapy and infliximab monotherapy over azathioprine monotherapy
Counseling Points
§ All patients should be counseled to avoid non-steroidal anti-inflammatory drugs as they 
may exacerbate Crohn’s disease
§ All patients should be counseled on using proper contraception while on 
immunomodulator therapy
§ Patients receiving corticosteroids should be counseled about importance of tapering 
therapy and the dangers of stopping their corticosteroid suddenly or taking their 
corticosteroid long term
§ All patients should be counseled about their increased risk for infections which should 
include methods and techniques that can be used to prevent infection
§ Good hand hygiene
§ Avoidance of sick contacts
52
Role of the Pharmacist in Crohn’s Disease
§ As many medications used in the treatment of 
Crohn’s disease have life-modifying adverse 
effects
§ Proper counseling
§ Helping patients with symptom relief 
§ As pharmacists are often able to see patients 
more than physicians
§ Symptom control
§ Therapeutic drug monitoring as needed
§ Cost of therapy
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What is Crohn’s Disease?
Epidemiology










Immune-mediated chronical intestinal condition
One of two types of Inflammatory Bowel Disease
Can involve any part of the gastrointestinal tract
Causes discontinuous lesions that are known as "skip" lesions
Diagnosis and Pertinent Laboratory Values




Eosinophil Sedimentation Rate ↑
C-Reactive Protein ↑
Serum Iron ↓
Serum Vitamin B12 ↓
Fecal Calprotectin ↑
Fecal Lactoferrin ↑
Stool Testing (to rule out C. difficile)






§ Lab testing is complementary and helps 
determine:
§ Disease severity
§ Complications of Crohn’s disease




Severity of disease 
will determine 






Goals of Therapy in Crohn’s Disease Crohn’s Disease Activity Index (CDAI)
American College of Gastroenterology’s Approach in Mild-Moderate Crohn’s 
Disease
Induction Therapy
§ Budesonide (Entocort EC®) 9 mg once daily in 
the morning for up to 8 weeks
§ Budesonide should be tapered by 3 mg 
increments every 2 to 4 weeks 
§ Preferred over prednisone due to a lower rate 
of systemic side effects
Maintenance Therapy
§ Sulfasalazine (Azulfidine®) 3 to 6 g/day for 
treatment of symptoms for up to 16 weeks
§ Has not been shown to be more 
effective than placebo in achieving 
mucosal healing
§ No maintenance treatment in patients with 
mild disease is recommended provided they 
are asymptomatic
American College of Gastroenterology’s Approach in Moderate-Severe Crohn’s 
Disease
Induction Therapy
§ Oral corticosteroids can be used short 
term to alleviate symptoms of 
moderate to severely active Crohn’s 
Disease
§ Vedolizumab (Entyvio®) and 
Natalizumab (Tysabri®) can also be 
used for induction of remission
§ Immunomodulators when patient is 
steroid-refractory
§ Anti-TNFα agents when patient is 
steroid-refractory or 
immunomodulator-refractory
§ Ustekinumab (Stelara®) given last line 
when patient is also Anti-TNFα 
therapy-refractory




§ Infliximab  
Induction/Maintenance in Fulminant Disease
American Gastroenterological Association’s Approach in Moderate-Severe 
Crohn’s Disease Maintenance Therapy
Induction Therapy
§ In patients whose symptomology 
persists despite steroid, 
immunomodulator, or 5-ASA therapy:
§ Anti-TNFα therapy
OR
§ Anti-TNFα therapy + 
immunomodulator therapy
Drug Cost/Dose Average Cost/Year
Adalimumab (Humira®) $2,565 $30,780
Certolizumab (Cimzia®) $4,293 $51,516
Infliximab (Remicade®) $5,790 $34,740
Ustekinumab (Stelara®) $21,769 $130,614
Vedolizumab (Entyvio®) $6,413 $38,478
Cost of Biologic Therapy
References
1. Biologics for Crohn’s Disease. Pharmacist’s Letter/Prescriber’s Letter. 2018;25(7):340706.
2. Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn’s Disease. F1000Prime Rep. 2015;7:44
3. Centers for Disease Control and Prevention. Epidemiology of the IBD. Centers for Disease 
Control and Prevention Website. Available from: https://www.cdc.gov/ibd/IBD-epidemiology.htm. 
Accessed July 10, 2019
4. Colombel JF, Sanborn WJ, Reinisch W, et al. Infliximab, Azathioprine, or Combination Therapy for 
Crohn's Disease. N Engl J Med. 2010:362(15);1383-1395. 
5. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy 
for Crohn’s Disease. N Engl J Med. 2016;375:1946-1960.
6. Freeman HJ. Use of the Crohn’s Disease Activity Index in Clinical Trials of Biological Agents. 
World J Gastroenerol. 2008:14(26);4127-4130. 
7. Freidman S, Blumberg RS. Inflammatory Bowel Disease. In: Jameson J, Fauci AS, Kasper DL, 
Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 20th edition. 
online. New York(NY): McGraw-Hill; 2018. Available from http://accesspharmacy.com. Accessed 
July 20, 2019.
8. Hemstreet BA. Inflammatory Bowel Disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells 
BG, Posey L, editors. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. online. New York 
(NY): McGraw-Hill; 2018. Available from http://www.accesspharmacy.com. Accessed: July 20, 
2019
9. Lexi-Drugs Online™.  Lexi-Comp Online™.  Hudson (OH): Lexi-Comp, Inc.; 2019.  Available 
from: http://online.lexi.com.  Accessed:  July 30, 2019.
10. Lichtenstein GR, Loftus EV, Issacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical 
Guideline: Management of Crohn’s Disease in Adults.  Am J Gastroenterol. 2018;113(4):481-517.
11. Papamichael K, Cheifetz AS, Melme GY, et al. Appropriate Therapeutic Drug Monitoring of 
Biologic Agents for Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 
2019;17(9):1655-1668.
12. Peppercorn MA, Kane SV. Clinical manifestations, diagnosis and prognosis of Crohn Disease in 
adults. In: Rutgeerts P (editor). UpToDate Online. Waltham (MA):UpToDate;2019. Available from 
http://www.uptodate.com. Accessed July 17, 2019
13. Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. NOD proteins: regulators of 
inflammation in health and disease. Nat Rev Immunol. 2014:14(1):9-23.
14. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Diseases: A 
Systematic Review. BioDrugs. 2017;31(4):299-316.
15. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American Gastroenterological 
Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic 
Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn’s Disease. 
Gastroenterology. 2013;145(6):1459-1463.
16. Veauthier B, Hornecker JR. Crohn’s Disease and Management. Am Fam Physician. 
2018;98(11):661-669. 
References
1. Biologics for Crohn’s Disease. Pharmacist’s Letter/Prescriber’s Letter. 2018;25(7):340706.
2. Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn’s Disease. F1000Prime Rep. 2015;7:44
3. Centers for Disease Control and Prevention. Epidemiology of the IBD. Centers for Disease 
Control and Prevention Website. Available from: https://www.cdc.gov/ibd/IBD-epidemiology.htm. 
Accessed July 10, 2019
4. Colombel JF, Sanborn WJ, Reinisch W, et al. Infliximab, Azathioprine, or Combination Therapy for 
Crohn's Disease. N Engl J Med. 2010:362(15);1383-1395. 
5. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy 
for Crohn’s Disease. N Engl J Med. 2016;375:1946-1960.
6. Freeman HJ. Use of the Crohn’s Disease Activity Index in Clinical Trials of Biological Agents. 
World J Gastroenerol. 2008:14(26);4127-4130. 
7. Freidman S, Blumberg RS. Inflammatory Bowel Disease. In: Jameson J, Fauci AS, Kasper DL, 
Hauser SL, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 20th edition. 
online. New York(NY): McGraw-Hill; 2018. Available from http://accesspharmacy.com. Accessed 
July 20, 2019.
8. Hemstreet BA. Inflammatory Bowel Disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells 
BG, Posey L, editors. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. online. New York 
(NY): McGraw-Hill; 2018. Available from http://www.accesspharmacy.com. Accessed: July 20, 
2019
9. Lexi-Drugs Online™.  Lexi-Comp Online™.  Hudson (OH): Lexi-Comp, Inc.; 2019.  Available 
from: http://online.lexi.com.  Accessed:  July 30, 2019.
10. Lichtenstein GR, Loftus EV, Issacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical 
Guideline: Management of Crohn’s Disease in Adults.  Am J Gastroenterol. 2018;113(4):481-517.
11. Papamichael K, Cheifetz AS, Melme GY, et al. Appropriate Therapeutic Drug Monitoring of 
Biologic Agents for Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 
2019;17(9):1655-1668.
12. Peppercorn MA, Kane SV. Clinical manifestations, diagnosis and prognosis of Crohn Disease in 
adults. In: Rutgeerts P (editor). UpToDate Online. Waltham (MA):UpToDate;2019. Available from 
http://www.uptodate.com. Accessed July 17, 2019
13. Philpott DJ, Sorbara MT, Robertson SJ, Croitoru K, Girardin SE. NOD proteins: regulators of 
inflammation in health and disease. Nat Rev Immunol. 2014:14(1):9-23.
14. Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of Biologics in Chronic Diseases: A 
Systematic Review. BioDrugs. 2017;31(4):299-316.
15. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American Gastroenterological 
Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti–TNF-a Biologic 
Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn’s Disease. 
Gastroenterology. 2013;145(6):1459-1463.
16. Veauthier B, Hornecker JR. Crohn’s Disease and Management. Am Fam Physician. 
2018;98(11):661-669. 
